spec sheet8 rows
Elunetirom (ABX-002) is an investigational thyromimetic prodrug designed to deliver selective thyroid hormone receptor beta (TR-beta) activation preferentially to the central nervous system while limiting the systemic thyroid effects that make native thyroid hormone unsuitable as a drug. It belongs to the same CNS-penetrating prodrug class as sobetirome and its amide prodrug Sob-AM2, for which preclinical studies have shown brain-targeted TR-beta engagement that stimulates oligodendrocyte differentiation, promotes myelin repair, and lowers very long chain fatty acids in models of demyelination and X-linked adrenoleukodystrophy. By recreating thyroid hormone action in the brain without body-wide hyperthyroidism, such agents are being explored as add-on treatments for mood disorders and neurological disease. As of the mid-2020s elunetirom remained in clinical trials and had not been approved for any use.
- Brain-targeted thyroid signaling
- Better working memory (rodents)
- Neuroplasticity and BDNF programs
- Lower peripheral thyroid load
- Brain-targeted thyroid signaling without body-wide effects
- Thyromimetics can affect heart rate and rhythm
- Possible effects on bone with thyroid-hormone-like activity
- May lower cholesterol and shift thyroid-related lab values
Overview
Elunetirom is a thyromimetic, a synthetic compound that reproduces certain effects of natural thyroid hormone by activating thyroid hormone receptors. It is selective for the beta subtype of the receptor (TR-beta) and is engineered to cross the blood-brain barrier so that it can act within the brain [1]. It is being developed by Autobahn Therapeutics under the code ABX-002 [2][3].
The compound grew out of academic work on brain-penetrant thyromimetics. Thyroid hormone plays an important role in the formation and repair of myelin, the insulating sheath around nerve fibers, and in a range of brain functions, but thyroid hormone itself acts throughout the body and can strain the heart and bones. Selective TR-beta agonists that reach the brain were pursued as a way to obtain central effects with a wider safety margin; chemists designed prodrug forms of the thyromimetic sobetirom that are converted to the active agent and deliver much more of it to the brain after systemic dosing [1].
Elunetirom has been studied chiefly as an adjunctive (add-on) therapy for depression. Early-phase testing evaluated its safety and pharmacology in healthy volunteers [3], and it has advanced into phase 2 trials as an add-on treatment for major depressive disorder and for depressive episodes in bipolar disorder [2]. Preclinical research has also explored thyromimetics of this class for demyelinating and metabolic disorders of the nervous system, such as multiple sclerosis and adrenomyeloneuropathy, and reported improvements in cognitive impairment in rodent models.
Elunetirom is an experimental agent. It has not been approved by any regulatory agency, its uses remain investigational, and its efficacy and long-term safety in humans are still being determined [2][3].
Mechanism
Elunetirom is a selective of thyroid hormone receptor beta (TR-beta), one of the nuclear receptors through which thyroid hormone regulates gene transcription. By activating TR-beta, it reproduces selected actions of thyroid hormone on target genes while aiming to spare the TR-alpha-mediated effects that most strongly influence the heart [1].
The molecule is designed as a that crosses the and is then converted into the active thyromimetic within the central nervous system, concentrating its activity in the brain rather than the periphery [1]. Because thyroid hormone signaling influences myelination, neuronal metabolism, and mood-related circuits, activating TR-beta in the brain is the proposed basis for its investigational use in depression and in demyelinating disorders. Pro-cognitive effects reported in animal models have been attributed to this central thyromimetic action.
receptor fingerprint
FAAH (brain)Prodrug substrate
Thyroid receptor beta (TRβ)Preferring agonist
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Research compound, laboratory use only, with rodent-stage data and no human safety record. Thyromimetics as a class have to be careful about the heart, bone, and metabolic effects of overshooting thyroid signaling; the brain-targeted prodrug design exists to limit exactly that, but that is a goal, not a proven human profile.
Subjective profileweighing the evidence above
Early and genuinely interesting, but nowhere near ready. The brain-targeted design exists precisely to spare the heart and bone from thyroid overshoot, and that remains a design goal rather than a proven human profile. Rodent working-memory data is not a reason to take a thyromimetic.
Resources
This entry is here for reference.
Research
- 2014first citedA selective thyroid hormone beta receptor agonist enhances human and rodent oligodendrocyte dif…
- 2023most recentMaternal Administration of the CNS-Selective Sobetirome Prodrug Sob-AM2 Exerts Thyromimetic Eff…
- 1.Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration
- 2.A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
- 3.A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects
- 4.Myelin repair stimulated by CNS-selective thyroid hormone action.
- 5.Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.
- 6.Sobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain.
- 7.A selective thyroid hormone beta receptor agonist enhances human and rodent oligodendrocyte differentiation.
- 8.Selective Thyroid Hormone Receptor-Beta (TRbeta) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
- 9.Maternal Administration of the CNS-Selective Sobetirome Prodrug Sob-AM2 Exerts Thyromimetic Effects in Murine MCT8-Deficient Fetuses.
- 10.Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
- 11.A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.
11 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is Elunetirom used for?
Cognition; it is researched as a brain-targeted thyroid hormone mimic for memory and neuroplasticity.
How does Elunetirom work?
It is a prodrug that the brain enzyme FAAH cleaves to release a TRβ thyroid agonist right in the brain, switching on energy and BDNF plasticity genes while keeping thyroid effects off the rest of the body.
Is Elunetirom well-researched?
No; the data is preclinical (rodent) and it is a research compound.
What are the main side effects?
Unknown in humans; the design is meant to avoid the heart and metabolic effects of thyroid overactivity, but that is not yet shown in people.
Limitations of the evidence
- Investigational; the human safety profile is still being established
Adverse effects
- Thyromimetics can affect heart rate and rhythm
- Possible effects on bone with thyroid-hormone-like activity
- May lower cholesterol and shift thyroid-related lab values
Notes and cautions
- Not approved for any use